Case Report: Linezolid-associated toxic optic neuropathy in patients with pulmonary tuberculosis: case series and mini review
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- FRONTIERS IN PHARMACOLOGY16 · #1547236 · 2025
- 피인용
- Web of Science 4Scopus 3
- FWCI (Scopus)
- 1.04
- JCR IF
- JCR 2024 4.8
- ISSN
- 1663-9812
저자
- 윤희진제1저자Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
- 김수진교신저자Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
- 한광언Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
- 최은정Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea
- 이지은Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
초록
Linezolid is a useful second-line medication for the treatment of tuberculosis that is resistant to multiple drugs. However, long-term therapy can cause side effects, such as optic neuropathy. We describe three cases of progressive painless bilateral visual loss in patients taking long-term linezolid therapy for multidrug-resistant and extensively drug-resistant tuberculosis. We reviewed the literatures and identified 58 cases of linezolid optic neuropathy. Discontinuation of linezolid resulted in a marked improvement in vision, however it was not complete in all patients. Knowledge of visual monitoring of patients undergoing long-term linezolid therapy is important for physicians and ophthalmologists.
키워드
case reportextensive drug resistancelinezolidmuti-drug registancetoxic optic neuropathytuberculosisDRUG-RESISTANT TUBERCULOSISMULTIDRUG-RESISTANTINHIBITIONRECOVERYREGIMENSEFFICACYSAFETY
식별자
- Scopus EID
- 2-s2.0-105006516109
- WoS UID
- 001495122300001



로그인
연구물 목록으로